Melinta Therapeutics’ Phase 3 trials of Baxdela Document Challenges in Antibiotic Selection in Patients Treated for ABSSSI

Phase 3 Subgroup Analysis Presented at Society of Hospital Medicine Meeting

Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced an upcoming presentation of findings from the Baxdela™ (delafloxacin) Phase 3 clinical program.  These findings suggest Baxdela may represent an important treatment option for patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI), particularly obese patients, diabetics, and the elderly, who typically provide challenges in antibiotic selection and dosing.  In particular, obese patients, representing 42% of the Baxdela Phase 3 clinical program, were demonstrated to be aggregators of co-morbidities, with twice the rate of important co-morbidities when compared to non-obese patients.  These factors are important considerations for physicians when choosing an antibiotic.